Finance

Lists
Why is 300147 down 2.25%?
Dive Deeper
300147:SHE
Xiangxue Pharmaceutical Co Ltd
CNÂ¥4.35
-2.25%
(-0.100) 1D
Nov 4, 3:04:58 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 300147...
Open
CNÂ¥4.40
High
CNÂ¥4.41
Low
CNÂ¥4.22
Mkt. cap
2.94B
Avg. vol.
15.71M
Volume
16.08M
52-wk high
CNÂ¥11.23
52-wk low
CNÂ¥3.91
EPS
-CNÂ¥2.19
Shares outstanding
661.28M
No. of employees
3K
Open
CNÂ¥4.40
High
CNÂ¥4.41
Low
CNÂ¥4.22
Mkt. cap
2.94B
Avg. vol.
15.71M
Volume
16.08M
52-wk high
CNÂ¥11.23
52-wk low
CNÂ¥3.91
EPS
-CNÂ¥2.19
Shares outstanding
661.28M
No. of employees
3K
News stories
From web sources and news partners
Profile
Xiangxue Pharmaceutical Co., Ltd. also known as XPH, is a Chinese pharmaceutical company. It was headquartered in Guangzhou Economic and Technological Development Zone, Guangzhou, the capital of the Guangdong Province. The company started in a place that near to the tourist spot Luogang Xiangxue, thus called itself Xiangxue. Xiangxue Pharmaceutical was a constituent of SZSE 200 Index, but was removed in January 2017; it was inserted to SZSE 700 Index instead at the same time. SZSE 200, 300 and 700 Indexes are subsets of SZSE 1000 Index, the latter is a stock market index for the top 1,000 companies by free-float adjusted capitalization. In July 2017 Xiangxue was also removed from SZSE Component Index, an index for top 500 companies of the exchange. Wikipedia
About Xiangxue Pharmaceutical Co Ltd
CEO-
Employees2.66K
FoundedDec 29, 1997
Headquarters-
SectorPharmaceutical industry
Industry-
Websitexphcn.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
449.49M
354.16M
348.62M
361.35M
Cost of goods sold
388.48M
228.49M
252.20M
245.33M
Cost of revenue
388.48M
228.49M
252.20M
245.33M
Research and development expenses
22.13M
10.74M
11.51M
15.03M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
75.98M
89.74M
95.27M
83.96M
Operating expense
108.42M
97.82M
111.19M
94.56M
Total operating expenses
496.91M
326.31M
363.40M
339.89M
Operating income
-47.41M
27.85M
-14.78M
21.46M
Other non operating income
-14.25M
-944.82K
-2.74M
-381.05M
EBT including unusual items
-1.00B
-89.20M
-147.88M
-128.98M
EBT excluding unusual items
-144.93M
-40.82M
-81.08M
-228.30M
Income tax expense
30.08M
9.14M
5.48M
4.49M
Effective tax rate
-3.00%
-10.25%
-3.70%
-3.48%
Other operating expenses
4.05M
-3.18M
-1.15M
1.64M
Net income
-1.03B
-111.44M
-157.38M
-148.97M
Net profit margin
-229.21%
-31.47%
-45.14%
-41.23%
Earnings per share
-
-
-
-
Interest and investment income
175.82K
23.18K
15.53K
131.33M
Interest expense
-83.47M
-67.75M
-63.58M
-38.71K
Net interest expenses
-83.30M
-67.73M
-63.56M
131.29M
Depreciation and amortization charges
-
-
-
-
EBITDA
15.22K
75.28M
37.21M
68.89M
Gain or loss from assets sale
-8.92M
-
-107.04K
107.04K
Upcoming events
AI content may include mistakes. Learn more
Google apps